Results 51 to 60 of about 19,015 (246)

ESVM Guideline on peripheral arterial disease [PDF]

, 2019
International ...
, , , Belch, Jill, Boc, Vinko, Brodmann, Marianne, Bulvas, Miroslav, Canning, Caitriona, Carpentier, Patrick H., Chraim, Ali, Colgan, Mary-Paula, Dimakakos, Evangelos, Dorigo, Walter, Frank, Ulrich, Gottsäter, Anders, Heiss, Christian, Houston, Graeme, Kahan, Thomas, Lawall, Holger, Lindstedt, Isak, Madaric, Juraj, Mahe, Guillaume, Martini, Romeo, Mazzolai, Lucia, Nikol, Sigrid, Olinic, Dan Mircea, Pernod, Giles, Poredoš, Pavel, Przywara, Stanislaw, Pécsvárady, Zsolt, Quéré, Isabelle, Righini, Marc, Roztocil, Karel, Schlager, Oliver, Stanek, Agata, Terlecki, Piotr, Vasic, Dragan, Visonà, Adriana, Wautrecht, Jean-Claude   +38 more
core   +5 more sources

A Simplified Three‐Tailed N‐Alkyl Phosphoramidate Lipid Platform Enables Inguinal Adipose‐Accumulated mRNA Delivery for Anti‐Obesity Therapy

Advanced Science, EarlyView.
This study develops an mRNA therapy encoding a long‐acting GLP‐1/FGF21 fusion protein. A three‐tailed ionizable lipid engineered three‐component lipid nanoparticle delivers the mRNA to inguinal adipose tissue. In obese mice, this targeted, dual‐hormone treatment potently reduces body weight, fat mass, presenting a localized strategy for metabolic ...
Bin Ma, Yunxuan Liu, Huijuan Zhang, Yian Fang, Yizhe Xue, Junsheng Xue, Ziqiong Jiang, Tianyan Zhou, Yanyun Hao, Fei Xie, Lei Miao   +10 more
wiley   +1 more source

Gut microbiota mediates semaglutide attenuation of diabetes-associated cognitive decline

Neurotherapeutics
Diabetes-associated cognitive decline (DACD), characterized by cognitive impairment, is a serious complication of diabetes mellitus (DM). Research has shown that semaglutide, a novel glucagon-like peptide-1 receptor agonist, has neurotrophic and ...
Liqin Qi, Huimin Kang, Feihui Zeng, Menglan Zhan, Cuihua Huang, Qintao Huang, Lijing Lin, Guanlian He, Xiaoying Liu, Xiaohong Liu, Libin Liu   +10 more
doaj   +1 more source

Reflections on the Sulphonylurea Story. A Drug Class at Risk of Extinction?:Or A Drug Class Worth Reviving? [PDF]

, 2019
The role of sulphonylureas (SUs) in modern clinical practice poses ongoing clinical debate. With the advent of newer agents in diabetes management, there is an increasing shift away from the prescribing of SUs, but not necessarily to more effective ...
Janbon M, Loubatieres A, Mailhot J, Rados DV, The University Group Diabetes Program   +4 more
core   +2 more sources

Effectiveness of Pre‐Transplant Dual GLP‐1 Receptor Agonist and SGLT2 Inhibitor Therapy on All‐Cause Mortality in Organ Transplantation Candidates with Obesity and Type 2 Diabetes: a Target‐Trial Emulation

Advanced Science, EarlyView.
This target trial emulation in solid organ transplant candidates with obesity and type 2 diabetes evaluates whether pre‐transplant dual therapy with GLP‐1 receptor agonists plus SGLT2 inhibitors is associated with post‐transplant mortality and kidney graft outcomes compared with monotherapy or usual care, using multinational electronic health records ...
Yu‐Nan Huang, Min‐Yu Tsou, Pin‐Hung Li, Jo‐Ching Chen, Yen‐Liang Liu, Gideon Meyerowitz‐Katz, Tsung‐Hsun Tsai, Pen‐Hua Su   +7 more
wiley   +1 more source

Incretin-based therapy for type 2 diabetes mellitus is promising for treating neurodegenerative diseases [PDF]

, 2016
Incretin hormones include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). Due to their promising action on insulinotropic secretion and improving insulin resistance (IR), incretin-based therapies have become a new ...
Holscher, Christian, Li, Lin, Li, Yanwei
core   +1 more source

Selenoprotein H Functions as a PPARα Coactivator to Link Selenium Homeostasis to Hepatic Lipid Metabolism and Protect against Steatohepatitis

Advanced Science, EarlyView.
Our study identifies selenium deficiency as a hallmark of MASH pathogenesis. Dietary selenium supplementation enhances hepatic fatty acid oxidation (FAO) and attenuates MASH progression by activating the PPARα pathway via selenoprotein H (SELENOH). This selenium‐SELENOH‐PPARα nexus redefines the functional scope of selenoproteins, moving from redox ...
Yuwei Zhang, Yuchen Wang, Binbin Li, Xin Li, Chenyu Liu, Yanhao Chen, Cheng Tian, Dongmei Wang, Xiaosong Gu, Chunping Jiang, Yuda Wei, Qiurong Ding   +11 more
wiley   +1 more source

Effects of Once-Weekly Semaglutide on Cardiovascular Risk Factors and Metabolic Dysfunction-Associated Steatotic Liver Disease in Japanese Patients with Type 2 Diabetes: A Retrospective Longitudinal Study Based on Real-World Data

Biomedicines
Once-weekly semaglutide is a widely used glucagon-like peptide-1 receptor agonist (GLP-1RA) used for the treatment of type 2 diabetes (T2D). In clinical trials, semaglutide improved glycemic control and obesity, and reduced major cardiovascular events ...
Hisayuki Katsuyama, Mariko Hakoshima, Emika Kaji, Masaaki Mino, Eiji Kakazu, Sakura Iida, Hiroki Adachi, Tatsuya Kanto, Hidekatsu Yanai   +8 more
doaj   +1 more source

Efficacy, safety, and patient satisfaction with oral semaglutide: first single-centre clinical experience

Journal of International Medical Research, 2023
Objective To explore the effects of oral semaglutide on glycaemic parameters, body weight, and satisfaction in the first recipient patients with type 2 diabetes mellitus in Slovenia, in a real-world clinical practice setting.
Miodrag Janić, Marija Jovanović, Andrej Janež, Mojca Lunder   +3 more
doaj   +1 more source

Cardiovascular effects of Glucagon-like peptide 1 (GLP-1) receptor agonists [PDF]

, 2014
Patients with type 2 diabetes have a several-fold increased risk of developing cardiovascular disease when compared with nondiabetic controls. Myocardial infarction and stroke are responsible for 75% of all death in patients with diabetes, who present a ...
Andrei C Sposito, Francisco Kerr Saraiva
core   +1 more source